Melanotan 2

Melanotan 2 (MT-2) is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring peptide that regulates skin pigmentation and other physiological processes. Developed originally at the University of Arizona in the 1980s as a potential tool for studying melanogenesis ^[1], MT-2 was designed to be a more potent and metabolically stable version of alpha-MSH. Researchers hoped the compound could reduce UV exposure required for tanning, thereby lowering skin cancer risk associated with sun-seeking behavior.

MT-2 acts as a non-selective agonist at multiple melanocortin receptor ^[1]s: MC1R, MC3R, MC4R, and MC5R. Activation of MC1R on melanocytes triggers the upregulation of eumelanin production, the dark brown-black pigment responsible for skin darkening. Because MT-2 binds all four receptor subtypes rather than selectively targeting MC1R, it produces a range of effects beyond pigmentation, including spontaneous erections (via MC4R in the central nervous system), appetite suppression (MC3R and MC4R), and changes in sebaceous gland activity (MC5R).

Early phase I clinical trials demonstrated statistically significant increases in skin reflectance and visual pigmentation scores in subjects receiving subcutaneous MT-2 injections. In one landmark trial published in JAMA Dermatology, subjects experienced measurable tanning after only five low doses administered every other day. The same study documented that 8 of 10 male subjects developed clinically significant penile erections after administration, an unexpected finding that eventually led researchers to develop PT-141 (bremelanotide) as a targeted sexual dysfunction treatment. Despite promising early data, MT-2 has never completed the full FDA approval process for any indication, and it remains unapproved for human therapeutic use in the United States, European Union, and most other jurisdictions.

The compound is available through research peptide vendors and is widely used off-label by individuals seeking accelerated tanning, particularly those who tan poorly due to fair skin phenotypes (Fitzpatrick types I-II). Users must understand that the long-term safety profile of MT-2 is incompletely characterized, that the compound can cause changes to existing moles and nevi that mimic melanoma, and that its use is not endorsed by dermatology or endocrinology professional bodies. Responsible use requires pre-use dermatological evaluation and periodic skin monitoring throughout any course of administration.